Oral Presentation: OP02: The role of PTPN2 SNP in the pathogenesis of fibrosis in Crohn’s DiseaseScientific Programme 2019
Oral Presentation: OP07: Analysing intestinal organoids in a multi-omics, systems biology framework to investigate functional processes affected in Crohn’s disease due to autophagy impairmentScientific Programme 2019
Oral Presentation: OP09: Histological remission and mucosal healing in a randomised, placebo-controlled, phase 2 study of etrasimod in patients with moderately to severely active ulcerative colitisScientific Programme 2019
Oral Presentation: OP10: Systems genomics of ulcerative colitis: combining GWAS and signalling networks for patient stratification and individualised drug targeting in ulcerative colitisScientific Programme 2019
Oral Presentation: OP11: Organoids derived from inflamed intestinal biopsies of patients with ulcerative colitis lose their inflammatory phenotype during ex vivo cultureScientific Programme 2019
Oral Presentation: OP12: Targeting inflammation in ulcerative colitis by inhibiting glucose uptakeScientific Programme 2019
Oral Presentation: OP13: Molecular response to ustekinumab in moderate-to-severe ulcerative colitis by serum protein and biopsy gene expression analysis: Results from the UNIFI phase 3 induction studyScientific Programme 2019
Oral Presentation: OP14: Improved endoscopic outcomes and mucosal healing of upadacitinib as an induction therapy in adults with moderately-to-severely active ulcerative colitis: data from the U-ACHIEVE studyScientific Programme 2019
Oral Presentation: OP16: A randomised, multicentre, double-blind, placebo-controlled study of a targeted release oral cyclosporine formulation in the treatment of mild to moderate ulcerative colitis: efficacy resultsScientific Programme 2019
Oral Presentation: OP17: A molecular measure of inflammation in IBD patients based on transcriptional profiles from 2495 intestinal biopsiesScientific Programme 2019
Oral Presentation: OP19: Corticosteroid response rectal gene signature and associated microbial variation in treatment naïve ulcerative colitisScientific Programme 2019
Oral Presentation: OP20: Mucosal micoRNA profiles predict response to autologous stem-cell transplantation in Crohn’s DiseaseScientific Programme 2019
Oral Presentation: OP21: ABX464 is safe and efficacious in a proof of concept study in ulcerative colitis patientsScientific Programme 2019
Oral Presentation: OP23: CKD-506, a novel histone deacetylase (HDAC) 6 inhibitor, ameliorates colitis in various animal modelsScientific Programme 2019
Oral Presentation: OP24: Effectiveness and safety of ustekinumab 90 mg every four weeks in Crohn's diseaseScientific Programme 2019
Oral Presentation: OP25: Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn’s diseaseScientific Programme 2019
Oral Presentation: OP26: Long-term safety of vedolizumab in ulcerative colitis and Crohn’s disease: Final results from the GEMINI LTS studyScientific Programme 2019